GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Shiller PE Ratio

Blueprint Medicines (Blueprint Medicines) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2015. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Shiller PE Ratio Historical Data

The historical data trend for Blueprint Medicines's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Blueprint Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Blueprint Medicines's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Shiller PE Ratio falls into.



Blueprint Medicines Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Blueprint Medicines's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Blueprint Medicines's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.82/129.4194*129.4194
=-1.820

Current CPI (Dec. 2023) = 129.4194.

Blueprint Medicines Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.633 99.695 -0.822
201406 -0.733 100.560 -0.943
201409 -0.903 100.428 -1.164
201412 -1.251 99.070 -1.634
201503 -0.556 99.621 -0.722
201506 -0.810 100.684 -1.041
201509 -0.470 100.392 -0.606
201512 -0.580 99.792 -0.752
201603 -0.570 100.470 -0.734
201606 -0.700 101.688 -0.891
201609 -0.620 101.861 -0.788
201612 -0.750 101.863 -0.953
201703 -0.840 102.862 -1.057
201706 -0.860 103.349 -1.077
201709 -0.960 104.136 -1.193
201712 -1.230 104.011 -1.530
201803 -1.290 105.290 -1.586
201806 -0.620 106.317 -0.755
201809 -1.660 106.507 -2.017
201812 -1.830 105.998 -2.234
201903 -1.980 107.251 -2.389
201906 -2.040 108.070 -2.443
201909 -1.930 108.329 -2.306
201912 -1.350 108.420 -1.611
202003 -2.110 108.902 -2.508
202006 -2.280 108.767 -2.713
202009 11.160 109.815 13.152
202012 -1.530 109.897 -1.802
202103 -1.720 111.754 -1.992
202106 -1.860 114.631 -2.100
202109 -2.000 115.734 -2.236
202112 -5.400 117.630 -5.941
202203 -1.790 121.301 -1.910
202206 -2.680 125.017 -2.774
202209 -2.230 125.227 -2.305
202212 -2.650 125.222 -2.739
202303 -2.150 127.348 -2.185
202306 -2.190 128.729 -2.202
202309 -2.200 129.860 -2.193
202312 -1.820 129.419 -1.820

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (NAS:BPMC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Blueprint Medicines Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (Blueprint Medicines) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Executives
Ariel Hurley officer: Principal Accounting Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey W. Albers director, officer: CEO & President BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Christopher K. Murray officer: SVP, Technical Operations C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Fouad Namouni officer: President, R and D 535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
L. Becker Hewes officer: Chief Medical Officer C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter officer: Chief Scientific Officer C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee officer: Chief Commercial Officer C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi officer: Chief Commercial Officer 45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain officer: EVP and Chief Legal Officer C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel officer: Principal FAO BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus officer: Chief People Officer C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland officer: Chief Business Officer BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai director BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
George Demetri director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142